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The global war on drugs is driving the HIV/AIDS pandemic 
among people who use drugs and their sexual partners. 
Throughout the world, research has consistently shown 
that repressive drug law enforcement practices force drug 
users away from public health services and into hidden 
environments where HIV risk becomes markedly elevated. 
Mass incarceration of non-violent drug offenders also  
plays a major role in increasing HIV risk. This is a critical 
public health issue in many countries, including the United 
States, where as many as 25 percent of Americans infected 
with HIV may pass through correctional facilities annually, 
and where disproportionate incarceration rates are among 
the key reasons for markedly higher HIV rates among 
African Americans.
Aggressive law enforcement practices targeting drug  
users have also been proven to create barriers to HIV 
treatment. Despite the evidence that treatment of HIV 
infection dramatically reduces the risk of HIV transmission 
by infected individuals, the public health implications of  
HIV treatment disruptions resulting from drug law 
enforcement tactics have not been appropriately re-
cognized as a major impediment to efforts to control  
the global HIV/AIDS pandemic.
The war on drugs has also led to a policy distortion  
whereby evidence-based addiction treatment and public 
health measures have been downplayed or ignored. While 
this is a common problem internationally, a number of 
specific countries, including the US, Russia and Thailand, 
ignore scientific evidence and World Health Organization 
recommendations and resist the implementation of 
evidence-based HIV prevention programs – with devastat-
ing consequences. In Russia, for example, approximately 
one in one hundred adults is now infected with HIV.
In contrast, countries that have adopted evidence-based 
addiction treatment and public health measures have seen 
their HIV epidemics among people who use drugs – as well 
as rates of injecting drug use – dramatically decline. Clear 
consensus guidelines exist for achieving this success, but 
HIV prevention tools have been under-utilized while harmful 
drug war policies have been slow to change.
This may be a result of the mistaken assumption that drug 
seizures, arrests, criminal convictions and other commonly 
reported indices of drug law enforcement “success” have 
been effective overall in reducing illegal drug availability. 
EXECUTIVE SUMMARY
However, data from the United Nations Office on Drugs 
and Crime demonstrate that the worldwide supply of illicit 
opiates, such as heroin, has increased by more than  
380 percent in recent decades, from 1000 metric tons in 
1980 to more than 4800 metric tons in 2010. This increase 
coincided with a 79 percent decrease in the price of heroin 
in Europe between 1990 and 2009.
Similar evidence of the drug war’s failure to control drug 
supply is apparent when US drug surveillance data are 
scrutinized. For instance, despite a greater than 600 percent 
increase in the US federal anti-drug budget since the early 
1980s, the price of heroin in the US has decreased by 
approximately 80 percent during this period, and heroin 
purity has increased by more than 900 percent. A similar 
pattern of falling drug prices and increasing drug potency is 
seen in US drug surveillance data for other commonly used 
drugs, including cocaine and cannabis.
As was the case with the US prohibition of alcohol in 
the 1920s, the global prohibition of drugs now fuels 
drug market violence around the world. For instance, 
it is estimated that more than 50,000 individuals have 
been killed since a 2006 military escalation against drug 
cartels by Mexican government forces. While supporters 
of aggressive drug law enforcement strategies might 
assume that this degree of bloodshed would disrupt the 
drug market’s ability to produce and distribute illegal drugs, 
recent estimates suggest that Mexican heroin production 
has increased by more than 340 percent since 2004.
With the HIV epidemic growing in regions and countries 
where it is largely driven by injection drug use, and with 
recent evidence that infections related to injection drug use 
are now increasing in other regions, including sub-Saharan 
Africa, the time for leadership is now. Unfortunately, 
national and United Nations public health agencies have 
been sidelined. While the war on drugs has been fueling 
the HIV epidemic in many regions, other law enforcement 
bodies and UN agencies have been actively pursuing an 
aggressive drug law enforcement agenda at the expense 
of public health. Any sober assessment of the impacts 
of the war on drugs would conclude that many national 
and international organizations tasked with reducing the 
drug problem have actually contributed to a worsening of 
community health and safety. This must change.
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 The following action must be taken by national 
leaders and the United Nations Secretary 
General, as well as the United Nations Office on 
Drugs and Crime, UNAIDS and the Commission 
on Narcotic Drugs:
1. Acknowledge and address the causal links 
between the war on drugs and the spread of  
HIV/AIDS, drug market violence and other health 
(e.g., hepatitis C) and social harms.
2. Respond to the fact that HIV risk behavior 
resulting from repressive drug control policies 
and under-funding of evidence-based approaches 
is the main issue driving the HIV epidemic in 
many regions of the world.
3. Push national governments to halt the practice 
of arresting and imprisoning people who use 
drugs but do no harm to others.
4. Replace ineffective measures focused on the 
criminalization and punishment of people who 
use drugs with evidence-based and rights-
affirming interventions proven to meaningfully 
reduce the negative individual and community 
consequences of drug use.
5. Countries that under-utilize proven public health 
measures should immediately scale up evidence-
based strategies to reduce HIV infection and 
protect the health of persons who use drugs, 
including sterile syringe distribution and other 
safer injecting programs. Failure to take these 
steps is criminal.
6. The public and private sectors should invest  
in an easily accessible range of evidence-based 
options for the treatment and care for drug 
dependence, including substitution and  
heroin-assisted treatment. These strategies 
reduce disease and death, and also limit the size 
and harmful consequences of drug markets by 
reducing the overall demand for drugs.
7. All authorities – from the municipal to 
international levels – must recognize the clear 
failure of the war on drugs to meaningfully 
reduce drug supply and, in doing so, move 
away from conventional measures of drug law 
enforcement “success” (e.g., arrests, seizures, 
convictions), which do not translate into positive 
effects in communities.
8. Measure drug policy success by indicators that 
have real meaning in communities, such as 
reduced rates of transmission of HIV and other 
infectious diseases (e.g., hepatitis C), fewer 
overdose deaths, reduced drug market violence, 
fewer individuals incarcerated and lowered rates 
of problematic substance use.
9. Call for public health bodies within the United 
Nations system to lead the response to drug 
use and related harms and to promote evidence-
based responses. Other bodies, including the 
International Narcotics Control Board, should 
be subjected to independent external review to 
ensure the policies they promote do not worsen 
community health and safety.
10. Act urgently: The war on drugs has failed, and 
millions of new HIV infections and AIDS deaths 
can be averted if action is taken now.
  *  The recommendations from the Global Commission 
on Drug Policy’s 2011 “War on Drugs” report are  
summarized on the inside back cover of this report.
 SUMMARY OF THE RECOMMENDATIONS  
FROM THIS REPORT*
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 The War on Drugs and the  
HIV/AIDS Pandemic
 The global war on drugs is driving the HIV/AIDS 
pandemic among people who use drugs and their 
sexual partners. Today, there are an estimated  
33 million people worldwide living with the human 
immunodeficiency virus (HIV), and injecting drug use 
accounts for approximately one-third of new HIV 
infections occurring outside sub-Saharan Africa.1 While 
the annual number of new infections has been falling 
since the late 1990s, HIV incidence increased by more 
than 25 percent in seven countries over this time 
span, largely as a result of HIV transmission related 
to intravenous drug use.1 Five of these countries are 
in Eastern Europe and Central Asia, where the war on 
drugs is being aggressively fought and, as a result,  
the number of people living with HIV in this part of  
the world has almost tripled since 2000.1
 Globally, an estimated 16 million people inject illegal 
drugs, of whom about 3 million, or nearly one in five, 
are living with HIV.2 The average HIV prevalence among 
drug injectors in China, the United States of America 
and the Russian Federation – the three countries with 
the largest populations of injection drug users – is  
est-imated to be 12 percent, 16 percent and 37 percent, 
respectively.2 While these statistics point to a serious 
public health emergency, they do not expose the  
causal role that punitive drug law enforcement 
measures have played in driving the HIV epidemic 
within this population.3 As described below, treating 
drug use as a criminal offense fuels the HIV epidemic 
via several mechanisms.
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•	 Fear	of	arrest	drives	persons	who	use	drugs	under-
ground, away from HIV testing and HIV prevention  
services and into high risk environments.
•	 Restrictions	on	provision	of	sterile	syringes	to	drug	
users result in increased syringe sharing.
•	 Prohibitions	or	restrictions	on	opioid	substitution	
therapy and other evidence-based treatment  
result in untreated addiction and avoidable HIV  
risk behavior.
•	 Conditions	and	lack	of	HIV	prevention	measures	in	
prison lead to HIV outbreaks among incarcerated 
drug users.
•	 Disruptions	of	HIV	antiretroviral	therapy	result	in	 
elevated HIV viral load and subsequent HIV trans-
mission and increased antiretroviral resistance.
•	 Limited	public	funds	are	wasted	on	harmful	and	
ineffective drug law enforcement efforts instead of 
being invested in proven HIV prevention strategies.
 HOW THE DRUG WAR FUELS  
THE HIV PANDEMIC:
Upper Right: US marine patrols a poppy field in Afghanistan.  
Photo: United States Marine Corps (CC BY-NC 2.0)
Far Upper Right: An injecting drug user is injected with heroin, locally 
known as brown sugar, by his companion by a roadside in the eastern  
Indian city of Siliguri.  
Photo: Reuters / Rupak De Chowdhuri
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 Fear of Police and Stigma  
Drive HIV Risk Behavior
 Aggressive drug law enforcement practices aimed at  
suppressing the drug market drive drug-addicted 
individuals away from public health services and into 
hidden environments where HIV risk becomes markedly 
elevated.4 While police violence and torture of drug 
users have been widely reported,5 police harassment, 
confiscation of clean syringes and arrest for possession 
of syringes are also common, and all of these practices 
have repeatedly been shown to increase the sharing of 
used syringes and other risky drug injection practices.6,7
 Drug law enforcement’s contribution to HIV risk 
behavior can and should be avoided. A study published 
in the British medical journal The Lancet that explored 
how confrontations with police promote HIV risk 
behavior estimated that up to 19 percent of HIV 
infections among drug-addicted persons in Odessa, 
Ukraine could be avoided if abuse of drug users by 
police was halted.8
 In many settings, harsh drug laws have been shown 
to increase HIV risk behavior and push users away 
from public health services. The following words 
from a young woman in Moscow describe the fear 
caused by aggressive drug law enforcement:
  “ Fear. Fear. This is the very main reason. And not 
only fear of being caught, but fear that you will be 
caught, and you won’t be able to get a fix. So on top 
of being pressured and robbed [by police], there’s 
the risk you’ll also end up being sick. And that’s 
why you’ll use whatever syringe is available right 
then and there.”7
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 Mass Incarceration Fuels  
HIV Transmission
 Although most HIV transmission among drug users 
occurs in their communities, the mass incarceration of 
non-violent drug law offenders is also a significant factor 
in the epidemic. This is a critical public health issue in 
many countries, including the United States, where 
HIV prevalence and AIDS cases behind bars are many 
times higher than among the general population9,10 
and where as many as one-quarter of all HIV-infected 
Americans are estimated to pass through correctional 
facilities annually.11 Statistics for the US are consistent 
with global trends, with twenty low- to middle-income 
countries reporting HIV prevalence of greater than  
10 percent among prison inmates.12
 High rates of incarceration among drug users with or 
at risk of HIV infection are a matter of deep concern, 
given that incarceration has been associated with 
syringe sharing, unprotected sex and HIV outbreaks 
in many places around the world. Incarceration has 
been identified as a risk factor for acquiring HIV 
infection in countries of western and southern Europe, 
Russia, Canada, Brazil, Iran and Thailand.13 Research 
has also shown that the sharing of used syringes is 
the primary reason for the spread of HIV in prison 
settings, and public health investigations using viral 
genetic techniques have proven that HIV outbreaks 
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have emerged as a result of syringe sharing among 
inmates.13-15 As described below, incarceration also 
drives risk of HIV infection and disease by interrupting 
antiretroviral HIV treatment.
 Research conducted in the United States, where ethnic 
minorities are many times more likely than whites to be 
incarcerated for drug-related offenses, has found that 
disproportionate incarceration rates are one of the key 
reasons for the markedly elevated rates of HIV infection 
among African Americans.16,17 This is an urgent public 
health concern, as African Americans represent just  
12 percent of the US population but, in recent years, 
have accounted for more than 50 percent of the nation’s 
new HIV infections.18
 The global emphasis on drug law enforcement has also 
led to mass incarceration of drug users in compulsory 
“drug detention centers,” particularly in places where 
HIV is rapidly spreading among this population.19 
Although these centers vary in their design and 
operation, reports consistently indicate that these 
facilities fail to offer evidence-based addiction treatment 
or HIV care. Documented cases of forced labor, torture 
and other human rights abuses are widespread in 
these settings.20 Despite recent criticism by a range of 
health and human rights organizations, as well as the 
United Nations and US government, compulsory drug 
detention centers continue to operate, especially in 
China and Southeast Asia.21,22
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Inmates sit in a recreation room 
where they are housed due to 
overcrowding at the California 
Institution for Men state prison in 
Chino, California, June 3, 2011. 
The Supreme Court has ordered 
California to release more than 
30,000 inmates over the next 
two years or take other steps to 
ease overcrowding in its prisons 
to prevent “needless suffering 
and death.” California’s 33 adult 
prisons were designed to hold 
about 80,000 inmates and now 
have about 145,000. The US has 
more than 2 million people in state 
and local prisons. It has long had 
the highest incarceration rate in 
the world.  
Reuters / Lucy Nicholson
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 Drug Law Enforcement Creates Barriers  
to Antiretroviral Therapy, Thereby  
Promoting HIV Transmission
 In addition to promoting the sharing of syringes and 
other HIV risk behavior, punitive drug law enforcement 
measures create barriers to HIV testing and treatment. 
There are several ways the criminalization of drug use 
may hinder or prevent access to essential treatment 
for drug users infected with HIV. These barriers to 
treatment include stigma and discrimination within 
healthcare settings, refusal of services, breaches 
of confidentiality, requirements to be drug-free as a 
condition of treatment, and the use of registries that 
lead to denial of such basic rights as employment and 
child custody.19,23 As a result, research has repeatedly 
shown that drug users have lower rates of antiretroviral 
therapy use and higher HIV/AIDS death rates.24
 Punitive drug law enforcement policies and practices 
also have broader implications for public health. 
Specifically, antiretroviral therapy is known to reduce the 
amount of human immunodeficiency virus circulating 
in the blood and sexual fluids, and recent clinical trials 
have proven that this effect also reduces rates of HIV 
transmission. As a result, many international agencies 
and national HIV programs have now shifted their focus 
to HIV “treatment as prevention” as a central HIV/AIDS 
strategy.25-28 This shift has major implications for the 
design of the global HIV/AIDS response since it further 
emphasizes the public health impact of providing all 
segments of the population, including persons who 
inject drugs, with access to HIV treatment.
 However, numerous studies have demonstrated that 
coercive drug law enforcement measures and the 
frequent incarceration of people who use drugs hinder 
them from seeking HIV testing and treatment, and 
contribute to the interruption of HIV treatment once 
it has begun.29 For example, a recent Canadian study 
showed that the greater the number of times an  
HIV-infected individual was incarcerated, the less likely 
that person was to adhere to antiretroviral therapy.30 
Similarly, a Baltimore study of HIV-infected patients 
found that even brief periods of incarceration were 
associated with a two-fold risk of syringe sharing and a 
greater than seven-fold risk of virological failure.31 The 
fact that drug law enforcement measures often disrupt 
HIV treatment efforts, promoting HIV drug resistance 
and increasing risk of HIV transmission, has yet to be 
appropriately addressed in national and international 
HIV prevention strategies.27,28 In fact, “treatment 
as prevention” and new prevention strategies such 
as scaled-up use of pre-exposure prophylaxis with 
antiretroviral medicines are rarely even considered or 
discussed by policymakers as responses to HIV among 
people who inject drugs.
Medicine for patients is lined up for distribution at the HIV/AIDS ward 
of Beijing YouAn Hospital December 1, 2011. The number of new  
HIV/AIDS cases in China is soaring, state media said, citing health  
officials, with rates of infections among college students and older 
men rising. The Chinese Center for Disease Control and Prevention 
issued figures showing 48,000 new cases in China in 2011, the official 
Xinhua news agency said. China’s government was initially slow to 
acknowledge the problem of HIV/AIDS in the 1990s. 
Reuters / David Gray
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 Where Public Health Approaches Are  
Ignored, the HIV Epidemic Is Out of Control
 In addition to increased HIV risk behavior and barriers 
to HIV treatment, the war on drugs has also led to the 
distortion of public policy, whereby evidence-based 
addiction treatment and public health interventions have 
been ignored or downplayed. In 2008, the Executive 
Director of the United Nations Office on Drugs and 
Crime acknowledged this reality, reflecting on the prior 
decade of drug control:
     “Public health, which is clearly the first principle of 
drug control, also needs a lot of resources. Yet the 
funds were in many cases drawn away into public 
security and the law enforcement that underpins it. 
The consequence was that public health was displaced 
into the background, more honored in lip service and 
rhetoric, but less in actual practice.”
 The emphasis on drug law enforcement has created 
legal barriers to evidence-based HIV prevention 
measures, such as the provision of clean syringes, and 
evidence-based addiction treatment methods, such as 
methadone maintenance therapy. These public health 
approaches have been proven to reduce HIV risk and 
are widely endorsed by major international medical 
and public health bodies.32,33 Methadone, for instance, 
is on the World Health Organization’s Model List of 
Essential Medicines, and various scientific reviews of 
the effectiveness of sterile syringe provision in reducing 
HIV risk have led the United Nations to strongly 
recommend sterile syringe provision.34
 Nevertheless, public health assessments have shown  
extremely low rates of coverage of proven interven-
tions, including in those settings where they are most 
urgently needed.24 For example, contrary to the advice 
of many scientific bodies and the recommendations 
of the World Health Organization, a number of 
countries, including the US and Russia, have resisted 
the implementation of evidence-based HIV prevention 
programs. In the US, Congress has recently reinstated 
the ban on federal funding of syringe exchange 
programs both domestically and abroad, just two years 
after lifting what had been a 21-year ban. Access to 
sterile syringes is limited in various other countries with 
high HIV rates among injecting drug users.
 Remarkably, despite the extensive body of clinical research 
proving the benefits of methadone maintenance therapy 
in reducing the individual and community harms of heroin 
use as well as HIV risk,35,36 the use of methadone remains 
limited in many countries and is illegal in Russia. Similarly, 
in the Central Asian republics and other countries of 
the former Soviet bloc, methadone programs tend to 
be “perpetual pilot programs” created in some cases in 
response to donor pressure but never brought to anything 
approaching the scale that would meet existing demand.
 A recent UN report describing the HIV prevention situation 
in Poland, which was critical of the nation’s anti-drug laws, 
noted that “in the context of HIV, there has been a gap in 
funding and work on HIV prevention, which in turn impacts 
the availability of prevention services including harm 
reduction measures.”37 Settings where HIV prevention 
measures have been curtailed as a result of economic 
concerns have been particularly vulnerable to increases in 
HIV risk among injection drug users. For instance, a greater 
than 10-fold increase in newly diagnosed HIV infections 
among injecting drug users has recently been reported 
from Greece during the first seven months of 2011.38 
Although the Russian Federation was recently investing 
close to US$800 million annually in HIV-related initiatives, 
less than one percent of this amount was targeted toward 
prevention for people who use drugs, among whom the 
Russian epidemic is concentrated.39 As a result of the lack 
of evidence-based addiction treatment and HIV prevention 
measures, about one in one hundred Russian adults is now 
infected with HIV (Figure 1).
 In spite of evidence of a long and expanding problem of 
heroin injection in many coastal areas of sub-Saharan Africa, 
especially the East African coast,2 a small methadone 
program in Mauritius and one begun in February 2010 
in Tanzania are virtually the only public sector opioid 
maintenance therapy programs south of the Sahara. 
Similarly, methadone remains effectively inaccessible in 
many parts of South and East Asia even where opiate 
injection is known to occur on a significant scale.
 Thailand is also an important case study, as the country is 
often credited with successfully reducing HIV among sex 
workers and their clients by distributing and promoting the  
use of condoms, along with other evidence-based mea-
sures. Among female commercial sex workers in Thailand, 
the estimated HIV prevalence has declined from a peak of 
more than 40 percent in 1995 to less than 5 percent  
in recent years. At the same time, however, Thailand has 
8
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maintained its longstanding war-on-drugs approach 
to illicit drug use, with drug users being considered 
“security threats.” The 2003 crackdown on suspected 
drug dealers resulted in the heinous extrajudicial killing  
of more than 2,500 persons.40 The crackdown and a 
continued repression made it less likely that people who  
use drugs would seek health services, including HIV  
treatment. Not surprisingly, therefore, while HIV pre-
valence among sex workers has declined dramatically, 
HIV rates among Thai drug users have remained 
persistently high, with estimated HIV prevalence 
approaching 50 percent in recent years (Figure 2).
 Even when different regions within countries are 
compared, higher HIV rates are clearly evident in areas 
with the most intense drug law enforcement. For instance, 
a study of the 96 largest US metropolitan areas found 
that measures of anti-drug “legal repressiveness” were 
associated with higher HIV prevalence among injectors  
and concluded: “This may be because fear of arrest  
and/or punishment leads drug injectors to avoid using 
syringe exchanges, or to inject hurriedly or to inject in 
shooting galleries or other multiperson injection settings  
to escape detection.”41
9
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 Where Addiction is Treated as a Health Issue, 
the Fight Against HIV is Being Won
 The experience in Russia, Thailand, the US and 
other countries where the war on drugs has been 
aggressively waged can be contrasted with countries 
that have adopted evidence-based addiction treatment 
and public health measures to address the HIV 
epidemic. In the latter countries, including a number 
of western European countries and Australia, newly 
diagnosed HIV infections have been nearly eliminated 
among people who use drugs, just as vertical 
transmission of HIV has been eliminated in countries 
where broad access to prevention of mother-to-child 
transmission of the virus is available.
 Indeed, as early as 1997, a global survey found that 
in 52 cities without syringe exchange, HIV prevalence 
increased by approximately 6 percent per year, whereas 
prevalence decreased by approximately 6 percent per 
year in the 29 cities with syringe exchange programs.42 
Since that time, similar results have consistently been 
reported from around the globe.32 For example, in 
Tallinn, Estonia, a country with one of the highest per 
capita HIV rates in Europe, a decrease in HIV infection 
among new injectors, from 34 percent to 16 percent, 
coincided with an increase in the number of syringes 
exchanged, from 230,000 in 2005 to 770,000 in 
2009.43 Similarly, in Portugal in 2001, the government 
decriminalized the use and possession of a modest 
quantity of illegal drugs for personal use, so as to focus 
on drug addiction as a public health issue. As a result, 
between 2000 and 2008, the number of new cases of 
HIV decreased from 907 to 267, while the number of 
cases of AIDS dropped from 506 to 108 among people 
there who inject drugs.44
 In Switzerland, the government responded to the 
burgeoning HIV epidemic among injection drug users 
in the 1980s by implementing innovative policies that 
provided clean syringes, supervised injecting facilities, 
easily accessible methadone therapy, heroin prescription 
and antiretroviral treatment.45 This strategy has led to a 
marked reduction in the number of new HIV infections 
linked to drug injection, from an estimated 68 percent in 
1985 to about 15 percent in 1997 and about 5 percent 
in 2009.45 Likewise, in British Columbia, Canada, the 
response to the explosive HIV epidemic that emerged 
among injection drug users in the mid-1990s has involved 
antiretroviral therapy, opioid substitution (including 
heroin prescription), syringe distribution and medically 
supervised injecting facilities, with resulting declines in 
HIV incidence and AIDS deaths among intravenous drug 
users there (Figure 3).
 While modest gains have been made with respect to 
treatment of opioid dependence, methamphetamine and 
other stimulants dominate illicit drug use in many parts 
of the world, and scientifically sound treatment options 
for them are more limited.19 The Commission sees an 
urgent need for more research on maintenance and 
other therapeutic approaches to managing stimulant use, 
including as a component of HIV prevention programs.
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The contents of a syringe  
exchange kit.  
Photo: Todd Huffman (CC BY 2.0)
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 HIV/AIDS Has Spread Because the War on 
Drugs Has Not Reduced Drug Supply
 Evidence that the war on drugs has fueled the HIV 
epidemic is irrefutable, and yet policy has been 
remarkably slow to change. This may largely be a result 
of the mistaken assumption that drug seizures, arrests, 
convictions and other commonly reported indices of 
drug law enforcement “success” have been effective at 
reducing drug supply. Indeed, stressing the importance 
of supply reduction tactics, the 2012 US National Drug 
Control Strategy concludes: “Reductions in supply 
are often closely tied to reductions in drug use and its 
consequences.”46 However, the assumptions about the 
benefits of drug law enforcement, implied each time the 
fruits of the latest “drug bust” are displayed before the 
public, have not been critically evaluated.
 Specifically, if the kind of intensive drug law enforce-
ment that has been practiced under the global war on 
drugs was achieving its stated objectives of meaningfully 
reducing drug supply, one would expect that increasing 
anti-drug expenditures would coincide with higher drug 
prices, decreased drug potency and fewer drugs available 
overall. However, evidence from around the world 
indicates that this has not been the case.
 According to data from the United Nations Office on 
Drugs and Crime, for example, the worldwide supply of 
illicit opiates such as heroin and opium has increased 
dramatically over the past 30 years. During this period, 
the global illicit opiate supply increased by more than  
380 percent overall, from 1000 metric tons in 1980 to 
more than 4800 metric tons in 2010 (Figure 4).47 This 
increase, the bulk of which occurred in Afghanistan, 
contributed to a greater than 75 percent decrease in  
the price of heroin in Europe between 1990 and 2009 
(Figure 5).
 Similar evidence of the drug war’s failure is provided by  
US drug surveillance data. For example, from 1981 to 
2011, the budget of the US Office of National Drug 
Control Policy increased by more than 600 percent 
(inflation-adjusted). However, despite increasing annual 
multibillion dollar investments in drug control, US  
gov-ernment data suggest an approximate inflation- and 
purity-adjusted decrease in heroin price of 80 percent,  
and a greater than 900 percent increase in heroin purity  
between 1981 and 2002, clearly indicating that ex-
penditures on interventions to reduce the supply of heroin 
into the United States were unsuccessful (Figure 6).*
 While the links between the war on drugs and HIV/AIDS 
warrant a focus on heroin, similar patterns emerge when 
anti-drug spending and indices of availability for other 
drugs are examined. For instance, through a variety of  
initiatives, the United States has directed considerable 
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Figure 5.  Average estimated heroin prices in Europe
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resources toward disrupting the cocaine trade. Plan 
Colombia, for example, was a multibillion dollar 
investment in the eradication of coca crops in Colombia 
through aerial and manual eradication, military training 
and support, and other means. Nevertheless, despite 
steady increases in the US budget for international supply 
reduction and counter-narcotics activities, the purity of 
cocaine has remained persistently high, while the purity- 
and inflation-adjusted price of cocaine in the US has 
concurrently dropped by more than 60 percent during 
this period (Figure 7). These long-term trends suggest 
that the overall supply of cocaine has overwhelmed 
law enforcement efforts and highlight how recent US 
government reports of diminishing cocaine supply to the 
US must be interpreted with a great deal of skepticism.48
 When cannabis, the drug that has been the central focus 
of the US government’s decades-long war on drugs, is 
considered, the results have been the same. Specifically, 
the potency- and inflation-adjusted price of cannabis in 
the US has declined by 33 percent while its potency 
has increased by 145 percent since 1990. In fact, the 
US National Institute on Drug Abuse has concluded that 
over the last 30 years of cannabis prohibition, the drug 
has remained “almost universally available to American 
12th graders,” with between 80 percent and 90 percent 
consistently reporting that the drug is “very easy” or 
“fairly easy” to obtain.49
 Recent United Nations Office on Drugs and Crime 
estimates have concluded that production of 
amphetamine-type stimulants has risen dramatically  
in the last decade, so much so that this class of illegal 
drug is now used more frequently than any but marijuana. 
However, aggressive drug law enforcement strategies 
targeting users of new synthetic drugs have the same 
negative public health effects.
 Taken together, these indicators clearly suggest that  
the overall drug supply (as evidenced by various 
indicators of increasing production, declining prices  
and increasing potency) has been largely unimpeded  
by the multibillion dollar investments that have gone  
into trying to disrupt supply through costly policing, 
arrests and interdiction efforts.
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Dramatic decline in domestic cocaine prices despite increasing spending for overseas 
drug suppression efforts by the United States
Note: Cocaine prices are purity- and inflation-adjusted and spending is inflation-adjusted. All prices expressed in 2011 USD.  
Source: US Office of National Drug Control Policy
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 The Drug War Spreads Violence  
in Addition to HIV
 Overwhelming evidence now clearly demonstrates  
that, analogous to the case of alcohol prohibition  
in the United States early in the 20th century, prohibition 
of drugs has contributed to increased levels of drug-
related mortality and drug market violence. Research 
from Switzerland, for example, has demonstrated that 
mortality levels among Swiss heroin users decreased as 
a result of opioid substitution treatment but increased 
following periods of intensified street-level drug 
law enforcement.50 Similarly, according to a recent 
systematic review of published research investigating 
the association between drug law enforcement and 
drug-related violence, virtually all studies on the subject 
have concluded that increased levels of enforcement 
activity have been associated with increased drug market 
violence.51 This study concluded that drug arrests and 
other drug law enforcement strategies that remove 
individuals from the lucrative drug market contribute  
to violence by having the “perverse effect of creating 
new financial opportunities,” resulting in fights over 
market share.
 While drug market violence can be viewed as a natural 
consequence of drug prohibition in nearly all countries, 
certain drug-producing regions have been particularly 
hard hit. In Mexico, for example, following a 2006 
government-initiated crackdown on drug cartels, 
drug-related violence involving the Mexican military, 
police and cartel factions has become entrenched on 
a massive scale. While accurate numbers are difficult, 
if not impossible, to obtain, the most widely used 
estimates suggest that the total number of deaths 
attributable to drug market violence since 2006 is in 
excess of 50,000 (Figure 8).52 Other estimates suggest 
that a further 10,000 individuals are missing and more 
than 1.5 million have been displaced by fighting related 
to drug control.
 While supporters of aggressive drug law enforcement 
strategies might assume that this degree of bloodshed 
would actually disrupt the ability of drug cartels to 
produce and distribute drugs, this has clearly not 
been the case, with recent estimates suggesting that 
Mexican heroin production has increased by more than 
340 percent since 2004 (Figure 9).
 “Crack” cocaine markets also deserve specific  
mention, in light of the related public health issues 
and the known connections between anti-crack law 
enforcement efforts and drug market violence.53 
Specifically, in the mid-1990s, the link between crack 
use and HIV infection was described in a study of 
US inner city neighborhoods which found that crack 
smokers were twice as likely as non-smokers to be 
infected with HIV.54 These results have since been 
confirmed by other research, including a recent 
Canadian study showing that rising rates of crack 
cocaine use predicted elevated HIV infection rates.55 
Given that intensive enforcement of anti-crack drug 
laws has resulted in increased drug market violence yet 
has failed to limit the availability of the drug, treating 
crack cocaine use as a public health concern, rather 
than a criminal justice issue, should be a priority.53
14
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Reporters stand next to a display of 
guns, bundles of marijuana and cocaine 
seized from the Sinaloa cartel during 
“Operation Pipeline Express” at a 
news conference in Phoenix, Arizona. 
Photo: Reuters / Joshua Lott
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Source: Government and news report estimates as reported in Transborder Institute, “Drug Violence in Mexico” and WM Consulting, 
“Mexico Total Dead, 2011”
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 Public Health Approaches Can Reduce  
Rates of Drug Use
 The Global Commission on Drug Policy’s previous 
report called for a public health approach to address the 
harms of drug use and drug prohibition. Unfortunately, 
the report was met with criticism from the US White 
House, with an Office of National Drug Control Policy 
spokesperson widely quoted as saying: “Drug addiction 
is a disease that can be successfully prevented and 
treated. Making drugs more available, as this report 
suggests, will make it harder to keep our communities 
healthy and safe.”56 This comment implies an inaccurate 
interpretation of our first report and is problematic for 
two reasons. First, US drug strategy remains focused 
on a criminal justice approach to drug use, with 
overwhelming federal and state drug control budgets 
dedicated to drug law enforcement and enforcement-
based prevention programs and interdiction rather than 
public health measures or the treatment of addiction. 
Second, the assumption that a public health approach 
to drug use will lead to increased rates of drug use or 
other adverse impacts on communities is not consistent 
with empirical evidence.
 A study completed as part of the World Health 
Organization’s World Mental Health Survey Initiative 
that looked at patterns of drug law enforcement and 
rates of drug use internationally concluded: “Globally, 
drug use is not distributed evenly and is not simply 
related to drug policy, since countries with stringent 
user-level illegal drug policies did not have lower levels 
of use than countries with liberal ones.”57 National 
studies of drug use patterns further support these 
trends. For example, a 10-year study of drug arrests 
from 93 large US metropolitan areas concluded that 
higher rates of drug arrests did not correspond to lower 
rates of drug injecting.58
 Rather than decreasing drug use, empirical evidence 
shows that drug law enforcement can have exactly 
the opposite effect. In the US, where one-eighth of 
young adults report that their biological father has 
been incarcerated at some time, a recent study found 
that paternal incarceration was significantly associated 
with adolescent drug use, even after taking into 
account other factors such as family background and 
individual characteristics.59 These types of unintended 
consequences of the war on drugs on families may  
help to explain why, for example, rates of cannabis  
use remain consistently higher in the US than in 
Portugal, where cannabis use has been decriminalized, 
or in the Netherlands, where cannabis sales have  
been quasi-legalized.44,60
 The evidence clearly suggests that health-based 
policies do not increase rates of drug use but rather 
have the potential to significantly decrease rates of 
use. Numerous reviews have proven, for example, 
that drug use is not increased by syringe exchange 
programs.61 Similarly, supervised injecting facilities, 
where drug users can inject street-obtained illicit drugs 
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In many parts of the world, the 
constant threat of police arrest, 
violence and incarceration at 
harm reduction drop-in centers, 
methadone clinics and other 
places where people who use 
drugs receive services minimizes 
the impact of these services. 
Photo: Citizen News Service  
(CC BY 3.0)
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the name of treaty compliance. Most recently, the  
INCB refused to join many other UN entities in 
condemning compulsory drug “treatment” centers and 
has consistently refused to condemn the application of 
the death penalty to drug-related crimes.
 Unfortunately, any sober assessment of the impacts  
of the war on drugs demonstrates that many national  
and international organizations tasked with reducing 
the drug problem have actually contributed to a 
worsening of community health and safety. This status 
quo must change.
 Fortunately, the longstanding silence regarding the 
harms of the war on drugs is being broken as a result 
of courageous leadership coming from many circles. 
The Vienna Declaration, as well as a range of other 
statements from leaders in science, medicine and  
public health, have highlighted the need for drug policies 
to be based on empirical evidence and not on drug  
war ideology.3,66
 In Latin America, Colombian President Juan Manuel 
Santos, Guatemalan President Otto Fernando Pérez 
Molina and Costa Rican President Laura Chinchilla  
have signaled their support for a rethinking of the  
war-on-drugs approach.
 Interestingly, in the United States, cracks in support for 
the war on drugs are also beginning to show, especially 
among those viewed to be traditional supporters. This 
change is appearing across the political spectrum, with  
conservative groups such as the Right on Crime initiative,  
as well as two US Republican presidential nomination 
candidates, recently leading the discussion about how 
to meaningfully reduce incarceration and end the war on 
drugs.67 In addition, in 2012, a number of US states will 
consider ballot initiatives to tax and regulate cannabis.
 We fully endorse these bold and pragmatic  
initiatives, which are entirely consistent with the  
Global Commission’s view of placing community health  
and safety as a priority in designing drug policies, and 
also with the Commission’s support for de-criminalization 
of drug use and experimentation with models of  
legal regulation.
 
under the supervision of medical staff, have proven to 
increase the use of addiction treatment and to reduce 
rates of drug injecting.62 Likewise, the initiation of a harm 
reduction approach to heroin use in Switzerland that 
included heroin prescription programs coincided with a 
sustained decrease in the number of new heroin users. 
Specifically, between 1990 and 2002, the annual number 
of new heroin users dropped by 82 percent, from 850 to 
150, and the overall population of heroin users declined 
by 4 percent per year during that time.63 A recent review 
of heroin prescription trials recently concluded: “The 
available evidence suggests an added value of heroin 
prescribed alongside flexible doses of methadone for 
long-term, treatment refractory, opioid users, to reach a 
decrease in the use of illicit substances, involvement in 
criminal activity and incarceration, a possible reduction 
in mortality; and an increase in retention in treatment.”64 
Decreased injection drug use despite expanded access 
to sterile syringes has now been reported from several 
different areas.32,43 Indeed, rather than increasing  
drug use, there is strong evidence to suggest that a 
public health approach to drug addiction can reduce  
rates of use.
 A Time for Leadership
 With the HIV epidemic continuing to grow among 
persons who use drugs, the time for national and 
international leadership is now. Within the United Nations 
system, key organizations, including the Joint United 
Nations Programme on HIV/AIDS and the World Health 
Organization, have for too long remained on the sidelines 
while the war on drugs has fueled the HIV epidemic. 
While the Office for the High Commissioner for Human 
Rights has pushed for more balanced and comprehensive 
policies, other UN organizations, such as the United 
Nations Office on Drugs and Crime and especially the 
International Narcotics Control Board (INCB), persist in 
pursuing an aggressive drug law enforcement agenda 
at the expense of public health approaches.65 While the 
INCB’s mandate includes ensuring that countries address 
medical needs for controlled substances, such as the use 
of methadone in treating opioid dependence, the board 
has a long history of decrying the spread of HIV linked  
to drug injection but doing little or nothing to push  
Russia and other countries that restrict medical access  
to methadone. A UN-supported institution that should  
play a key role in access to opioid replacement therapies 
rather chooses to praise repressive law enforcement in 
17
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 The Vienna Declaration: Scientific Support for 
the Global Commission’s Call for Change
 The Vienna Declaration is a scientific statement seeking 
to improve community health and safety by calling for 
evidence-based policies on illegal drugs. It was drafted 
by a writing committee of international experts in the 
fields of HIV/AIDS, drug policy and public health, under 
the leadership of the International AIDS Society.
 The Vienna Declaration was adopted as the official 
conference declaration of the XVIII International AIDS 
Conference, held in Vienna from July 18 to 23, 2010. 
This was one of the world’s largest public health 
conferences, attracting more than 20,000 delegates.  
It was convened by the International AIDS Society  
along with various international conference partners, 
including the World Health Organization, the Joint 
United Nations Programme on HIV/AIDS (UNAIDS),  
the United Nations Office on Drugs and Crime (UNODC) 
and the European Commission.
 The Declaration stressed that the war on drugs  
had not achieved its stated objectives and called  
for its harmful consequences to be acknowledged  
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and addressed. Following the Declaration’s launch, more  
than 20,000 individuals and more than 400 high-level 
organizations from every region of the globe endorsed 
the statement. Among the signatories to date are several 
Nobel laureates, thousands of scientific and academic 
experts, a diversity of health, faith-based, and civil society 
organizations, law enforcement leaders, and the judiciary 
from countries around the world. Signatories to the 
Vienna Declaration specifically call upon governments  
and international organizations, including the United 
Nations, to:
  • Undertake a transparent review of the effectiveness of 
current drug policies;
  • Implement and evaluate a science-based public health 
approach to address the individual and community harms 
stemming from illicit drug use;
  • Decriminalize drug users, scale up evidence-based drug 
dependence treatment options and abolish ineffective 
compulsory drug treatment centers that violate the 
Universal Declaration of Human Rights;
  • Unequivocally endorse and scale up funding for the 
implementation of the comprehensive package of HIV 
interventions spelled out in the WHO, UNODC and 
UNAIDS Target Setting Guide;
  • Meaningfully involve members of the affected 
community in developing, monitoring and implementing 
services and policies that affect their lives.
 Anand Grover, the UN Special Rapporteur on the right to 
the highest attainable standard of health, wrote of the 
Vienna Declaration:
   “ The right to health is an inclusive right, extending not 
only to timely and appropriate health care, but also to the 
underlying determinants of health, such as widespread 
implementation of harm-reduction initiatives. The 
criminalization of drug users does not benefit society 
and it worsens public health and contributes to serious 
human rights violations. Decriminalizing drug users, 
as outlined by the Vienna Declaration, would improve 
the health and welfare of people who use drugs and 
communities in general and must be recognized by 
governments, policy-makers, and individuals worldwide.”
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 1. Break the taboo. Pursue an open debate and  
promote policies that effectively reduce con-
sumption, and that prevent and reduce harms 
related to drug use and drug control policies. 
Increase investment in research and analysis  
into the impact of different policies and programs.
2. Replace the criminalization and punishment of 
people who use drugs with the offer of health and 
treatment services to those who need them.
3. Encourage experimentation by governments with 
models of legal regulation of drugs (with cannabis, 
for example) that are designed to undermine the 
power of organized crime and safeguard the health 
and security of their citizens.
4. Establish better metrics, indicators and goals to 
measure progress.
5. Challenge, rather than reinforce, common mis-
conceptions about drug markets, drug use and  
drug dependence.
6. Countries that continue to invest mostly in a law 
enforcement approach (despite the evidence) should 
focus their repressive actions on violent organized 
crime and drug traffickers, in order to reduce the 
harms associated with the illicit drug market.
7. Promote alternative sentences for small-scale  
and first-time drug dealers.
8. Invest more resources in evidence-based 
prevention, with a special focus on youth.
9. Offer a wide and easily accessible range of options 
for treatment and care for drug dependence, 
including substitution and heroin-assisted 
treatment, with special attention to those most  
at risk, including those in prisons and other 
custodial settings.
10. The United Nations system must provide lead-
ership in the reform of global drug policy. This 
means promoting an effective approach based  
on evidence, supporting countries to develop drug 
policies that suit their context and meet their 
needs, and ensuring coherence among various  
UN agencies, policies and conventions.
11. Act urgently: The war on drugs has failed, and 
policies need to change now.
 RECOMMENDATIONS OF THE GLOBAL COMMISSION ON  
DRUG POLICY’S 2011 “WAR ON DRUGS” REPORT
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